Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide

(2010) K A van Nifterik et al.   BRITISH JOURNAL OF CANCER

Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells

(2010) G. Germano et al.   CANCER RESEARCH

Trabectedin therapy for sarcomas

(2010) Paolo G Casali et al.   CURRENT OPINION IN ONCOLOGY

Trabectedin

(2010) Natalie J. Carter et al.   DRUGS

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

(2010) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

(2009) J. M. Del Campo et al.   ANNALS OF ONCOLOGY

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series

(2009) F. Grosso et al.   ANNALS OF ONCOLOGY

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

(2009) C. Forni et al.   MOLECULAR CANCER THERAPEUTICS

O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy

(2008) B. Verbeek et al.   BRITISH MEDICAL BULLETIN

Analysis of Gene Expression in Early-Stage Ovarian Cancer

(2008) S. Marchini et al.   CLINICAL CANCER RESEARCH

Role of homologous recombination in trabectedin-induced DNA damage

(2008) M. Tavecchio et al.   EUROPEAN JOURNAL OF CANCER

Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers

(2008) E. V. Stevens et al.   MOLECULAR CANCER THERAPEUTICS